NCT04592861

Carbon Ion RT for Locally Advanced Pancreatic Cancer

Terminated Phase 3 Last updated 5 January 2024

What this trial tests

Phase 3 trial testing carbon ion RT in Pancreatic Cancer in 5 participants. Terminated before completion.

Timeline

1 November 2020

Primary endpoint
24 August 2022

24 August 2022

Quick facts

Lead sponsor	Albert Einstein College of Medicine
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	1 November 2020
Primary completion	24 August 2022
Estimated completion	24 August 2022
Sites	1 location across China

Drugs / interventions tested

• carbon ion RT
• Chemotherapy drug — full drug profile →

Conditions studied

• Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Albert Einstein College of Medicine

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label randomized trial. Subjects will be randomized in a 2:1 ratio to receive carbon ion radiotherapy versus standard care for locally advanced pancreatic cancer. Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians. Subjects on the control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon ion radiotherapy) if disease progression occurs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. The Majority of United States Citizens With Cancer do not Have Access to Carbon Ion Radiotherapy.
   Foote RL, Tsujii H, Imai R, Tsuji H, et al · · 2022 · cited 7× · PMID 35875126 · DOI 10.3389/fonc.2022.954747